Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Zoldan

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Harefuah|September 1, 1990
[The diagnostic value of CT and MRI studies in brain-stem tumors]J Zoldan, M Goren, N Gadoth
Neurology|May 5, 1999
Psychosis: impact on the patient and familyE Melamed, G Friedberg, J Zoldan
The Journal of Rheumatology|December 1, 1990
Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosusA J Wysenbeek, L Leibovici, J Zoldan
Israel Journal of Medical Sciences|April 1, 1988
Transient regional and migratory osteoporosis. A possible neural mechanismI Klier, J Zoldan, Z Yosipovitch, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 1, 1987
Schizophreniform episode following measles infectionM Stoler, B Meshulam, J Zoldan, et al.
Clinical Neuropharmacology|October 28, 1998
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's diseaseG Friedberg, J Zoldan, A Weizman, et al.
Advances in Neurology|January 1, 1996
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's diseaseJ Zoldan, G Friedberg, A Weizman, et al.
Neurology|July 1, 1995
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonistJ Zoldan, G Friedberg, M Livneh, et al.
Lancet (London, England)|February 27, 1993
Ondansetron for hallucinosis in advanced Parkinson's diseaseJ Zoldan, G Friedberg, H Goldberg-Stern, et al.
Acta Obstetricia Et Gynecologica Scandinavica|January 1, 1987
Pre-eclampsia, "HELLP" syndrome and postictal cortical blindnessH Levavi, A Neri, J Zoldan, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Harefuah|September 1, 1990
[The diagnostic value of CT and MRI studies in brain-stem tumors]J Zoldan, M Goren, N Gadoth
Neurology|May 5, 1999
Psychosis: impact on the patient and familyE Melamed, G Friedberg, J Zoldan
The Journal of Rheumatology|December 1, 1990
Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosusA J Wysenbeek, L Leibovici, J Zoldan
Israel Journal of Medical Sciences|April 1, 1988
Transient regional and migratory osteoporosis. A possible neural mechanismI Klier, J Zoldan, Z Yosipovitch, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 1, 1987
Schizophreniform episode following measles infectionM Stoler, B Meshulam, J Zoldan, et al.
Clinical Neuropharmacology|October 28, 1998
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's diseaseG Friedberg, J Zoldan, A Weizman, et al.
Advances in Neurology|January 1, 1996
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's diseaseJ Zoldan, G Friedberg, A Weizman, et al.
Neurology|July 1, 1995
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonistJ Zoldan, G Friedberg, M Livneh, et al.
Lancet (London, England)|February 27, 1993
Ondansetron for hallucinosis in advanced Parkinson's diseaseJ Zoldan, G Friedberg, H Goldberg-Stern, et al.
Acta Obstetricia Et Gynecologica Scandinavica|January 1, 1987
Pre-eclampsia, "HELLP" syndrome and postictal cortical blindnessH Levavi, A Neri, J Zoldan, et al.
Pageof 2